Toward a human papillomavirus vaccine
D Rowen, C Lacey - Dermatologic clinics, 1998 - derm.theclinics.com
Papillomaviruses may infect cutaneous and mucosal epithelia, leading to the development
of proliferative lesions in a wide variety of vertebrates. The viruses are usually species …
of proliferative lesions in a wide variety of vertebrates. The viruses are usually species …
[HTML][HTML] HPV vaccination: the position paper of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV)
A Ciavattini, L Giannella, R De Vincenzo… - Vaccines, 2020 - mdpi.com
Human papillomavirus (HPV) related cervical cancer represents an issue of public health
priority. The World Health Organization recommended the introduction of HPV vaccination in …
priority. The World Health Organization recommended the introduction of HPV vaccination in …
Perspectives for the development of human papillomavirus vaccines and immunotherapy
LG Bermudez-Humaran, P Langella - Expert Review of vaccines, 2010 - Taylor & Francis
Human papillomavirus (HPV) is the most common sexually transmitted infection and is
responsible for 90–99% of cervical cancer (CxCa) cases. Although effective screening …
responsible for 90–99% of cervical cancer (CxCa) cases. Although effective screening …
Spotlight on the 9-valent HPV vaccine
PL Lopalco - Drug design, development and therapy, 2016 - Taylor & Francis
Starting in 2006, vaccination against human papillomavirus (HPV) has been progressively
implemented in most developed countries. Two vaccines have been successfully used, a …
implemented in most developed countries. Two vaccines have been successfully used, a …
HPV prophylactic vaccines: lessons learned from 10 years experience
JML Brotherton - Future Virology, 2015 - Taylor & Francis
When HPV vaccines were registered in 2006/2007, it was unclear whether these new and
type-specific prophylactic vaccines would be accepted by the community for cancer …
type-specific prophylactic vaccines would be accepted by the community for cancer …
Human papillomavirus vaccines for the prevention and treatment of cervical cancer.
The identification of human papillomavirus (HPV) as a cause of cervical cancer and its
precursor lesions indicates that HPV vaccines can potentially be used to prevent or treat …
precursor lesions indicates that HPV vaccines can potentially be used to prevent or treat …
HPV-vaccination against cervical carcinoma: will it really work?
G Gross - Medical microbiology and immunology, 2007 - Springer
Prophylactic HPV vaccination provides an opportunity to profoundly affect cervical cancer
incidence worldwide. The quadrivalent HPV VLP 6, 11, 16, 18 vaccine (Gardasil®) and the …
incidence worldwide. The quadrivalent HPV VLP 6, 11, 16, 18 vaccine (Gardasil®) and the …
Human papillomaviruses: Diseases, diagnosis, and a possible vaccine
RJ Greenblatt - Clinical Microbiology Newsletter, 2005 - Elsevier
The human papillomaviruses (HPVs) are a family of more than 80 serotypes that cause
pathologies, including common and genital warts. Long-term infections of the cervix, penis …
pathologies, including common and genital warts. Long-term infections of the cervix, penis …
An overview on the implementation of HPV vaccination in Europe
The discovery that the Human PapillomaVirus (HPV) is the necessary cause of cervical
cancer has led to the development of prophylactic vaccines. Cervical cancer is the second …
cancer has led to the development of prophylactic vaccines. Cervical cancer is the second …
[HTML][HTML] European Centre for Disease Prevention and Control issues guidance for the introduction of human papillomavirus (HPV) vaccines in European Union …
FF Hamers - Eurosurveillance, 2008 - eurosurveillance.org
Two prophylactic human papillomavirus (HPV) vaccines have been licensed in Europe: the
quadrivalent vaccine, Gardasil®(Sanofi Pasteur MSD) and the bivalent vaccine, Cervarix® …
quadrivalent vaccine, Gardasil®(Sanofi Pasteur MSD) and the bivalent vaccine, Cervarix® …